How to Set Up a Weight Management Clinic in Your Pharmacy: Complete Guide

The weight management landscape in UK pharmacy has shifted dramatically. With GLP-1 receptor agonists now firmly established as the most clinically effective medications available for obesity treatment, and with independent prescribers in pharmacy able to prescribe them legally, there has never been a better moment to build a structured weight management clinic within your pharmacy. This is not a passing trend. The demand from patients is real, the clinical evidence is robust, and the revenue opportunity for independent pharmacy is substantial.

This guide brings together everything you need to know — from the clinical governance framework and prescriber qualifications through to pricing structures, software infrastructure, GPhC compliance, and marketing your service effectively. Whether you are an existing independent prescriber exploring this service area or a pharmacy owner looking to expand your clinical offering, what follows is a practical, comprehensive roadmap. You can also explore the RxSure weight management service page to see how the platform supports this clinical workflow end-to-end.

Why Weight Management Is the Biggest Opportunity in UK Pharmacy Right Now

Obesity affects roughly 26% of adults in England, with a further 38% classified as overweight. Taken together, nearly two thirds of the adult population fall into a weight category where clinical intervention could meaningfully improve their health outcomes. Yet NHS waiting lists for structured weight management programmes remain long, access to specialist services is inconsistent across regions, and most GP practices do not have the capacity to provide the kind of ongoing support that weight management actually requires.

That gap is where pharmacy steps in.

Pharmacies already have the infrastructure, the patient-facing presence, and — increasingly — the prescribing authority to fill this gap. The introduction of GLP-1 receptor agonists such as semaglutide, tirzepatide, and liraglutide has changed what is clinically achievable. Trials have consistently shown weight loss outcomes of 10–20% or more in patients who use these medications alongside lifestyle support. Patients who have struggled for years with diet and exercise alone are seeing results they simply could not achieve through willpower. The interest from the public is enormous — and demand is outpacing NHS capacity by a significant margin.

The GLP-1 Revolution and What It Means for Pharmacy

For much of the last decade, the pharmacological options for weight management were limited. Orlistat was available but modest in effect for many patients. Liraglutide (Saxenda) existed but required daily injection and was associated with significant gastrointestinal side effects at the doses required for weight loss. The landscape changed fundamentally when semaglutide (Wegovy) demonstrated consistent, clinically meaningful weight loss across large-scale trials, followed by tirzepatide (Mounjaro) showing even greater efficacy in the SURMOUNT trial programme.

NICE NG246, published in 2023, formally endorsed both semaglutide and tirzepatide within managed access programmes, acknowledging the clinical and cost-effectiveness of these treatments within a structured weight management context. The guidance establishes who qualifies for treatment, what monitoring is required, and under what circumstances prescribing should continue or be discontinued.

For pharmacist independent prescribers, this opens a defined clinical pathway that can be delivered within a pharmacy setting — provided the governance framework, competence, and infrastructure are in place.

Revenue Potential: What a Weight Management Clinic Can Generate

The financial case is straightforward. An initial weight management consultation, covering full clinical assessment, eligibility determination, consent, and treatment planning, will typically be priced at £30–50. Follow-up consultations — monthly in the early stages, then every six to eight weeks as treatment stabilises — run at £20–30. For a patient on a GLP-1 medication, you are looking at a relationship that spans months to years, with multiple touchpoints generating both consultation revenue and, if you are dispensing through the same pharmacy, prescription income.

A pharmacy seeing just twenty weight management patients per month and offering monthly follow-up consultations could generate £1,000–2,000 per month in consultation fees alone, before any dispensing income. Scale that to fifty or a hundred patients and the numbers become a significant contributor to pharmacy revenue. More importantly, these patients tend to be engaged, motivated, and grateful for a service that is genuinely helping them — which builds loyalty and referrals over time.

You can explore how to structure this as a sustainable revenue stream in our private prescribing pricing guide, which covers fee-setting principles that apply directly to this service area.

Clinical Requirements and Prescriber Qualifications

Before you can run a weight management clinic and prescribe GLP-1 medications or any other pharmacological treatment, the legal and regulatory foundation must be correct. This is non-negotiable, and getting it right from the start protects both your patients and your pharmacy.

Independent Prescriber Annotation

To prescribe weight management medications — including semaglutide, tirzepatide, liraglutide, and orlistat in its prescription-only dose — as a pharmacist, you must hold the independent prescriber annotation on your GPhC registration. This annotation signifies that you have completed an accredited independent prescribing programme and are qualified to prescribe any medicine within your area of clinical competence.

The independent prescriber annotation is checked by the GPhC, and it must be current and active. You can verify your own registration status through the GPhC register. If you are a pharmacy owner looking to offer this service but do not personally hold the IP annotation, you will need to employ or contract a pharmacist independent prescriber to deliver clinical consultations.

Demonstrating Clinical Competence

Holding the IP annotation is necessary but not sufficient. The GPhC Standards for Pharmacy Professionals require that you practise only within your area of competence. For weight management specifically, competence encompasses:

• Understanding the pharmacology, dosing schedules, contraindications, and monitoring requirements for all medications you intend to prescribe
• Ability to conduct a thorough clinical assessment including cardiovascular risk, thyroid history, relevant comorbidities, and current medication review for interactions
• Knowledge of NICE NG246 and how its eligibility criteria apply in practice
• Familiarity with the management of common side effects, including when to adjust dosing and when to stop treatment
• Understanding of when to refer — to the GP, to a dietitian, or to specialist services

If you are new to this clinical area, completing specific CPD in obesity management and GLP-1 pharmacotherapy before seeing patients is strongly advisable. Several organisations, including the Royal Pharmaceutical Society, offer structured learning in this area. Recording this CPD in your portfolio demonstrates competence to the GPhC if they inspect.

Equipment and Physical Setup

A weight management clinic requires a private consultation room — not a screened area, but a genuinely private space where patients can discuss sensitive health information without being overheard. Within that space, you will need:

• Calibrated scales capable of measuring to at least 0.1 kg accuracy
• A height measure to calculate BMI precisely
• A blood pressure monitor (manual or validated automatic)
• A waist circumference tape measure
• Access to blood glucose testing or the ability to refer for HbA1c if clinical assessment indicates a need
• Adequate clinical record-keeping software (covered in detail later in this guide)

You do not need a phlebotomy suite or on-site blood testing in order to start, but having a clear pathway for referring patients for blood work when indicated — typically through their GP or a local private diagnostics service — is essential.

Patient Selection and Eligibility Criteria

Appropriate patient selection is one of the most important clinical decisions in running a weight management service. Not every patient who asks about GLP-1 medications is a suitable candidate, and prescribing to ineligible patients creates clinical risk, regulatory risk, and medicolegal exposure. Your patient selection criteria should align with NICE NG246 and the Summary of Product Characteristics (SmPC) for each medication.

BMI Thresholds

The primary eligibility criterion for weight management pharmacotherapy is BMI. The general thresholds used across current guidance are:

• BMI ≥ 30 kg/m²: Eligible for pharmacotherapy consideration in most patients
• BMI ≥ 27.5 kg/m² with at least one weight-related comorbidity: Eligible for treatment (comorbidities include type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
• Patients from Black, Asian, and minority ethnic backgrounds: Lower BMI thresholds may apply (typically 27.5 for treatment, 22.5 with comorbidities) given the increased cardiometabolic risk at lower BMI values in these populations

BMI thresholds are a starting point, not an endpoint. Always consider the individual clinical picture alongside the numbers.

Contraindications and Exclusion Criteria

Certain patient groups must be excluded from GLP-1 prescribing in a pharmacy-based weight management service. These include:

• Pregnancy or breastfeeding: GLP-1 medications are contraindicated in pregnancy. Women of childbearing potential should use effective contraception and be counselled to stop medication if they plan to conceive.
• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2): GLP-1 receptor agonists carry a theoretical risk based on rodent studies. Current guidance recommends excluding these patients.
• Severe gastrointestinal disease: Inflammatory bowel disease, gastroparesis, or other conditions significantly affecting GI motility may be worsened by GLP-1 therapy.
• Pancreatitis (personal history): History of acute pancreatitis requires careful consideration and in most cases represents a contraindication to GLP-1 therapy.
• Eating disorders: Patients with active or recent anorexia nervosa, bulimia, or other eating disorders require specialist assessment and should not receive pharmacotherapy for weight loss without specialist involvement.
• Severe renal or hepatic impairment: Dose adjustment or alternative prescribing may be required. Always check the current BNF entry and SmPC for each medication.
• Patients under 18: Weight management pharmacotherapy for minors requires specialist involvement and is not appropriate in a standard community pharmacy clinic.

Red Flags Requiring GP Referral

Some presentations during assessment should prompt referral to the GP or, where appropriate, secondary care before you proceed with weight management treatment:

• Unexplained weight loss (as opposed to the intentional weight loss the patient is seeking)
• Symptoms suggestive of secondary causes of obesity (Cushing’s syndrome, hypothyroidism not adequately managed)
• Uncontrolled cardiovascular disease
• New or undiagnosed type 2 diabetes identified during screening
• Severe mental health conditions, including active psychosis
• Bariatric surgery in the past two years

Having a clearly documented escalation pathway and referral template as part of your clinical governance framework gives you a structured response when these situations arise — rather than having to make an unplanned decision under pressure in the consultation room.

The Patient Pathway: Five Steps to Effective Weight Management Care

A structured, repeatable patient pathway is the backbone of a safe and scalable weight management service. The following five-step model gives patients a clear experience from first contact through to ongoing management, and gives your clinic a consistent process that can be audited and improved over time.

Step 1: Booking and Pre-Screening

The journey begins before the patient ever sits in front of you. A pre-consultation questionnaire — delivered digitally as part of your online booking process — captures the initial clinical information that determines whether a patient is likely to be eligible and allows you to prepare for the consultation properly.

Your pre-screening questionnaire should cover height and self-reported weight (to calculate approximate BMI), current medications, relevant medical history (including the exclusion criteria above), and the patient’s weight management goals. Patients who clearly fall outside eligibility criteria can be managed at the booking stage, saving time for both the patient and the prescriber.

Pre-screening also creates the first clinical record for the patient — and under GDPR, it is personal health data that must be handled accordingly. Make sure your digital infrastructure is compliant and that patients have given informed consent to their data being processed for clinical purposes.

Step 2: Initial Consultation

The initial consultation is the most important appointment in the pathway. It typically runs 30–45 minutes and should cover:

• Clinical assessment: Measured weight, height, BMI calculation, waist circumference, blood pressure
• Medical history review: Full history relevant to weight management, including cardiovascular history, diabetes status, thyroid conditions, gastrointestinal history, mental health history, and reproductive health for women
• Medication review: Current medications, with particular attention to medicines that cause weight gain (antipsychotics, corticosteroids, insulin, some antidepressants) and those that may interact with GLP-1 medications
• Eligibility determination: Formal application of BMI criteria and exclusion criteria
• Shared decision-making: Discussion of treatment options including lifestyle measures alone, orlistat, and GLP-1 medications, with clear explanation of expected benefits, risks, and side effects for each
• Consent: Written informed consent for the chosen treatment, covering what the medication does, the side effects, the monitoring required, and the patient’s responsibilities
• Treatment plan documentation: The clinical rationale for the chosen treatment must be recorded

At the end of the initial consultation, the patient should leave with a clear understanding of their treatment plan, their first prescription (or a clear explanation of why they are not receiving one), and their follow-up schedule.

Step 3: Treatment Plan and Initiation

Once eligibility is confirmed and consent obtained, initiate treatment at the lowest recommended starting dose for the chosen medication. The titration schedules for GLP-1 medications are specifically designed to minimise gastrointestinal side effects in the early weeks — deviating from these schedules without clinical reason is not best practice.

Provide written instructions for the patient on how to administer their medication (for injectable treatments), what to do if they miss a dose, and how to recognise side effects that warrant contacting the clinic. This information should also be documented in the clinical record as having been provided.

For patients on injectable GLP-1 medications, a brief injection technique demonstration or video resource is good practice and improves adherence in the early weeks when the injectable route feels unfamiliar.

Step 4: Follow-Up Consultations

Regular follow-up is where the clinical value of a structured pathway becomes clear. At each follow-up appointment:

• Weigh the patient and record the result, calculating change from baseline
• Review side effects — particularly nausea, vomiting, diarrhoea, or constipation in GLP-1 patients — and adjust dose titration accordingly
• Check blood pressure
• Review adherence and explore any barriers the patient is experiencing
• Assess response to treatment: if a patient has not lost at least 5% of their initial body weight after 12 weeks at the optimal dose, the clinical case for continuing pharmacotherapy should be reviewed
• Update the clinical record with current weight, observations, any dose changes, and the plan going forward

The frequency of follow-up consultations depends on the phase of treatment. Monthly reviews are appropriate during dose titration. Once the patient is stable on their maintenance dose and tolerating treatment well, reviews every six to eight weeks can be sufficient for most patients.

Step 5: GP Communication and Shared Care

Notifying the patient’s GP is a professional obligation and a clinical governance requirement. Your GP notification letter should be sent at the time of initiating treatment and should include: the patient’s weight management history, the clinical rationale for prescribing, the medication and dose, the monitoring plan, and your contact details as the prescribing pharmacist.

Some GPs will want to take over prescribing for long-term weight management medications, particularly once the patient is stable. Others will be grateful for the pharmacy to continue managing the patient but want to be kept informed. Either way, maintaining an open communication channel with the GP is in the patient’s best interest and protects you clinically.

GP notifications should be documented in the clinical record, including the date sent and the method of communication.

Medications You Can Prescribe

Understanding the medications available for weight management — their mechanisms, dosing schedules, monitoring requirements, and side effect profiles — is fundamental to safe prescribing. The following covers the main agents used in current UK pharmacy weight management practice.

Semaglutide (Wegovy / Ozempic)

Semaglutide is a GLP-1 receptor agonist administered once weekly by subcutaneous injection. As Wegovy (the licensed weight management formulation), it is titrated over 16 weeks from 0.25 mg weekly up to the maintenance dose of 2.4 mg weekly. Ozempic (0.5 mg and 1 mg doses) is licensed for type 2 diabetes but is sometimes used off-label for weight management at lower doses — in a weight management clinic context, Wegovy is the appropriate formulation to prescribe.

Clinical trials (STEP programme) demonstrated average weight loss of approximately 15% of body weight over 68 weeks on semaglutide 2.4 mg, with higher responders achieving significantly greater losses. Semaglutide also has evidence for cardiovascular risk reduction, which has recently led to a new indication for reducing cardiovascular events in patients with established cardiovascular disease.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most pronounced during dose titration and typically improve as the body adjusts. Slow titration is the most effective strategy for managing these effects. Always refer to the current BNF semaglutide entry and the Wegovy SmPC for the complete side effect and contraindication profile.

Tirzepatide (Mounjaro)

Tirzepatide is the newest and most efficacious agent currently available in UK pharmacy for weight management. It is a dual GIP and GLP-1 receptor agonist — the first of its class — and is licensed for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related comorbidity.

The SURMOUNT trial programme demonstrated average weight loss of approximately 20% at the highest dose (15 mg weekly), with many patients achieving weight loss previously associated only with bariatric surgery. Tirzepatide is administered once weekly by subcutaneous injection, titrated over 20 weeks from 2.5 mg to the maintenance dose of either 5 mg, 10 mg, or 15 mg, depending on tolerability and response.

The side effect profile is similar to semaglutide — predominantly gastrointestinal during titration — and the same principles of slow titration and patient education apply. Refer to the current BNF tirzepatide entry and the Mounjaro SmPC for full prescribing information.

Liraglutide (Saxenda)

Liraglutide was the first GLP-1 receptor agonist licensed specifically for weight management in the UK. It is administered once daily by subcutaneous injection, titrated over five weeks from 0.6 mg to the maintenance dose of 3 mg daily. Its efficacy is lower than that of semaglutide and tirzepatide — average weight loss of approximately 8–9% in trials — and the daily injection burden can affect long-term adherence for some patients.

That said, liraglutide remains a clinically appropriate option for some patients, particularly those who are unsuitable for weekly injections due to adherence concerns, or in cases where cost is a primary consideration. Saxenda is licensed for adults with a BMI of 30 or above, or 27 with at least one weight-related comorbidity.

Orlistat

Orlistat is a lipase inhibitor that works by reducing the absorption of dietary fat by approximately 30%. It is available both over-the-counter at the 60 mg dose (Alli) and on prescription at the 120 mg dose (Xenical). In a private weight management clinic, you would typically prescribe Xenical 120 mg three times daily with main meals.

Orlistat is less effective than GLP-1 medications — average weight loss of around 3–5% beyond diet and exercise alone — and produces significant gastrointestinal side effects (steatorrhoea, oily discharge, faecal urgency) if patients do not adhere to a low-fat diet. However, it has no contraindication based on cardiovascular or thyroid history, making it suitable for patients who cannot receive GLP-1 medications. It is also substantially cheaper, which matters for patients with budget constraints.

Monitoring for orlistat includes annual review of fat-soluble vitamin status (vitamins A, D, E, and K), as orlistat can impair their absorption. Patients should be advised to take a multivitamin supplement at a time of day when they are not taking orlistat.

Clinical Governance and Medication Safety

Running a private weight management clinic means operating as the responsible clinician for your patients’ treatment. There is no other prescriber co-signing your decisions. That responsibility requires a robust clinical governance framework — not because inspection demands it (though it does), but because it is how you protect patients and practise safely.

Cardiovascular Assessment

Weight management medications, particularly GLP-1 receptor agonists, are used in a patient population that often carries elevated cardiovascular risk. A baseline cardiovascular assessment at the initial consultation should include blood pressure measurement, documentation of any known cardiovascular disease, and a clinical judgement about cardiovascular risk using a validated tool (such as QRISK3) where clinically indicated.

Patients with uncontrolled hypertension (blood pressure consistently above 180/110 mmHg) should have this addressed before initiating weight management pharmacotherapy. GLP-1 medications generally have a modest blood pressure-lowering effect, which is beneficial in most patients but warrants monitoring.

Thyroid and Endocrine Screening

Unmanaged hypothyroidism is a contributing cause of obesity that, if present, should be treated before or alongside weight management pharmacotherapy. Your initial assessment should include a direct question about thyroid history and, where clinically indicated, referral for thyroid function testing before prescribing.

As noted earlier, personal or family history of medullary thyroid carcinoma or MEN2 syndrome is a contraindication to GLP-1 therapy and must be actively screened for in the history.

Drug Interactions

A comprehensive medication review is essential at the initial consultation. Key interactions to consider include:

• Insulin and sulfonylureas: GLP-1 medications reduce blood glucose, and combining them with insulin or sulfonylureas in patients with type 2 diabetes increases the risk of hypoglycaemia. If prescribing a GLP-1 medication to a patient on insulin, always communicate with the GP or diabetologist about potential insulin dose reduction.
• Oral medications with narrow therapeutic windows: GLP-1 medications slow gastric emptying, which can affect the absorption of oral medications. This is particularly relevant for warfarin, levothyroxine, and oral contraceptives — patients on these medications should be specifically counselled and, where appropriate, INR or other relevant monitoring should be undertaken.
• Weight-promoting medications: Some patients will be on medications that cause weight gain — antipsychotics, corticosteroids, certain antidepressants. Discuss this with the patient; in some cases a review of these medications with the GP may be appropriate alongside weight management treatment.

Dose Adjustment Protocols

Your clinical governance documentation should include written protocols for dose adjustment decisions. When should you hold a dose titration? When should you reduce the dose? When should you stop treatment? These decisions should not be made ad hoc — having documented protocols means that your decisions are consistent, defensible, and in line with clinical guidance.

Specific circumstances where dose adjustment should be considered include: persistent nausea or vomiting at the current dose after more than four weeks; significant gastrointestinal side effects affecting quality of life; dehydration; unexplained pain; or any new clinical finding that changes the risk-benefit balance.

Side Effect Management

Anticipatory guidance to patients about side effects improves adherence and reduces anxiety-driven discontinuation. Your patient education materials and consultation notes should cover: what side effects to expect, when they typically occur, what self-management measures help (eating smaller meals, avoiding fatty foods, staying hydrated), and when to contact the clinic versus when to seek urgent care.

Red flag symptoms requiring prompt medical attention include: severe persistent abdominal pain (potential pancreatitis), symptoms of gallbladder disease (right upper quadrant pain, especially after eating), significant tachycardia, or signs of severe dehydration.

Documentation and Record-Keeping

Documentation is not paperwork for its own sake. It is the evidence of the clinical decisions you made, the information you gave the patient, and the care you provided. In a private prescribing context, your records are the primary protection for both the patient and yourself if anything goes wrong or if the GPhC inspect your practice.

What Must Be Recorded

Every patient encounter — initial consultation and each follow-up — should generate a clinical record that includes:

• Date and time of the consultation
• Current weight, height, and BMI (measured, not self-reported, at every encounter)
• Blood pressure reading
• Medication prescribed: name, dose, route, frequency, quantity, and duration
• Clinical rationale for the prescription (especially important if deviating from standard titration or continuing treatment despite modest response)
• Side effects discussed and reported by the patient
• Patient’s response to treatment (percentage weight loss from baseline)
• Any dose adjustments made and the reason for them
• Information given to the patient
• Consent documented (at initiation and re-confirmed if treatment plan changes significantly)
• GP notification sent: date and method
• Plan for next appointment

Consent Documentation

Informed consent for weight management pharmacotherapy should be documented in writing. Your consent process should ensure the patient understands: what condition is being treated, what the medication does, the anticipated benefits and the timeframe for seeing them, the common and serious side effects, the alternatives to the chosen treatment, what happens if they miss doses or stop treatment, and their right to withdraw from treatment at any time.

A signed consent form, stored in the patient’s clinical record, is best practice. Digital consent — where the patient signs electronically through your booking or records platform — is equally valid provided it is stored securely and is auditable.

Audit Trails

Your record-keeping system must provide a clear audit trail — meaning it is possible to see not only what was recorded but when each entry was made and by whom. Retrospective editing of clinical records without a documented reason is a serious governance failure. The system you use should make it difficult or impossible to delete or change records without leaving a trace.

You can read more about how RxSure’s platform handles audit trails and clinical documentation in our compliance certificate management guide.

Pricing Your Weight Management Service

Pricing a private clinical service involves balancing what the service costs to deliver, what the market will bear in your area, and what represents fair value for patients. Weight management is a service where patients are highly motivated and willing to invest in results — but it is also a service where your pricing will be compared against online-only competitors, some of whom operate without the same standards of clinical oversight that your pharmacy provides.

Consultation Fee Structure

A typical pricing structure for a pharmacy weight management clinic in the UK looks like this:

• Initial consultation (30–45 minutes): £35–55
• Follow-up consultation (15–20 minutes): £20–30
• Telephone or video review: £15–20

Pricing at the lower end of these ranges is appropriate if you are building volume in a competitive local market. Pricing at the higher end is justified if you are providing a more comprehensive initial assessment, operate in a higher-cost area, or are positioning your service as a premium offering compared to generic online alternatives.

Medication Costs and Dispensing

In addition to consultation fees, patients will pay for their medications. Wholesale prices for GLP-1 medications can fluctuate, and supply chain constraints have affected availability at various points since these medications came to market. Being transparent with patients about medication costs from the outset avoids surprises and builds trust.

Approximate retail prices for patients (at the time of writing) typically range from £150–200 per month for semaglutide (Wegovy) and £120–180 per month for tirzepatide (Mounjaro), depending on dose. Orlistat 120 mg is significantly cheaper — typically £20–40 per month — which makes it a genuinely accessible option for patients with budget constraints.

Package Pricing

Many pharmacies find that offering a package — combining an initial consultation plus a set number of follow-up appointments — improves patient retention and simplifies billing. A common model is:

• 3-month starter package: Initial consultation plus two monthly follow-ups — approximately £80–100
• 6-month management programme: Initial consultation plus five follow-ups — approximately £130–160

Package pricing works well because it sets a clear financial commitment up front, which correlates with better patient adherence. Patients who have paid for a six-month programme are more likely to attend follow-up appointments and stay engaged with their treatment than those who pay per appointment.

Revenue Projections

To illustrate the opportunity: a pharmacy running a weight management clinic with two half-day sessions per week, seeing four patients per session, and maintaining an ongoing cohort of seventy five patients at various stages of follow-up, could realistically generate £3,000–5,000 per month in consultation fees. This is before any income from dispensing weight management medications through the pharmacy itself.

For detailed guidance on structuring private prescribing fees, see our complete pricing guide for pharmacy private prescribing services.

Software and Digital Infrastructure

Running a weight management clinic on paper or across disconnected systems is both inefficient and a governance risk. The right digital infrastructure transforms a weight management service from a drain on your time into a scalable, well-documented clinical operation. If you are evaluating platforms, our guide to choosing private prescription software covers the five platform types, compliance requirements, and pricing models in detail.

Online Booking and Pre-Screening

Your booking system should allow patients to self-book appointments online at any time, including outside pharmacy opening hours. This is commercially important — patients researching weight management services at 11pm should be able to book an appointment rather than being told to ring in the morning. It also reduces the administrative burden on your staff.

Integrated pre-screening questionnaires, completed by the patient at the time of booking, feed initial clinical information directly into the patient’s record and allow the prescriber to review it before the appointment. This significantly improves consultation efficiency and means you arrive at the first appointment already knowing the patient’s approximate BMI, relevant medical history, and current medications.

Clinical Templates and Record-Keeping

Structured clinical templates for weight management consultations ensure consistent documentation across every patient encounter. A good template prompts the prescriber to record all the required fields — weight, BMI, blood pressure, medications prescribed, rationale, side effects, next review date — and generates a structured clinical note that can be retained securely.

Templates also protect against the cognitive load of trying to remember everything that needs to be documented while simultaneously conducting a clinical assessment. With the right template, documentation becomes a checklist rather than a memory exercise.

Private Prescription Generation

Your software should generate compliant private prescriptions electronically, including all legally required prescription details: prescriber name, qualifications, and address; patient name and date of birth; medication name, form, dose, quantity, and directions; date and prescriber signature.

Human Medicines Regulations 2012 specifies what must appear on a private prescription. Non-compliant prescriptions can be refused by the dispensing pharmacy, which creates an inconvenient situation for the patient and reflects poorly on your service.

Payment Processing

Integrated payment processing — ideally available at the time of booking or immediately after the consultation — simplifies the financial side of running a private service. Patients who pay at the time of booking are more likely to attend. Automated payment receipts and invoices reduce the administrative time spent on billing.

Patient Tracking and Progress Monitoring

The ability to view a patient’s weight loss trend over time — graphically — is both clinically useful and motivationally powerful for patients. Being able to show a patient that they have lost 12% of their body weight over six months, displayed as a clear downward trend, reinforces their engagement with the service and their confidence in continuing treatment.

Progress tracking should also flag patients who are overdue for follow-up, who have not met the minimum response threshold at the optimal dose, or who have missed appointments. Automated reminder messages (SMS or email) significantly reduce did-not-attend rates.

The RxSure platform brings together booking, pre-screening, clinical templates, prescription generation, payments, and patient tracking in a single system built specifically for pharmacy private prescribing services.

GPhC Compliance and Inspection Readiness

The GPhC Standards for Pharmacy Professionals and the Standards for Registered Pharmacies apply to private prescribing services just as they apply to every other aspect of pharmacy practice. If the GPhC visit your pharmacy, they will look at your clinical service areas with the same scrutiny they apply to dispensing accuracy and controlled drug management. Our GPhC compliance guide for private prescribing covers the inspection framework in full.

What the GPhC Will Look For

During an inspection that covers private prescribing, the GPhC inspectors are likely to look at:

• Whether prescribers hold the appropriate annotation and can demonstrate clinical competence for the services they are providing
• Whether patient records are complete, contemporaneous, and securely stored
• Whether consent has been appropriately obtained and documented
• Whether there is evidence of clinical governance — standard operating procedures, audit activity, and a process for managing clinical incidents
• Whether GP notification is being undertaken systematically
• Whether private prescriptions meet the legal requirements under Human Medicines Regulations 2012

Being well-prepared for inspection is not about performing for the regulator. It is about actually running the service to the standard the regulator expects — which is the standard your patients deserve.

Standard Operating Procedures

Your weight management service should be supported by written standard operating procedures (SOPs) covering: patient eligibility assessment, initial consultation process, prescribing and dose titration, follow-up review process, GP notification, management of adverse events, clinical record-keeping, and out-of-hours safety netting for patients.

SOPs do not need to be lengthy documents. They need to be practical, accurate, and actually used. A one-page SOP that the prescriber refers to regularly is more valuable than a fifty-page document that sits in a folder.

Audit Requirements

Clinical audit is a professional requirement for independent prescribers and a GPhC expectation. For a weight management service, meaningful audit topics include: percentage of patients achieving 5% weight loss at 12 weeks; rate of treatment discontinuation and reasons; completeness of GP notification; rate of adverse events and side effects requiring dose adjustment; and percentage of patients completing the 6-month programme.

Audit findings should be used to improve the service — this is the point of doing them. If your audit shows that 40% of patients are not completing their follow-up appointments, that finding should prompt a review of your reminder processes, your appointment scheduling, or your patient engagement approach.

GP Notification as a Compliance Requirement

GP notification is both a professional obligation and an expectation of the GPhC. It is also simply good clinical practice — the patient’s GP needs to know what medications they are on. Your records should show that a GP notification was sent for every patient at the time of initiating pharmacotherapy, and that any significant changes to treatment (dose changes, stopping medication, adverse events) were also communicated.

In our compliance guide, we cover how to maintain a systematic approach to clinical documentation that makes inspection readiness an ongoing state rather than a last-minute scramble.

Marketing Your Weight Management Clinic

You can run a clinically excellent weight management service that nobody knows about. Marketing is not optional if you want to build a patient base that makes the service viable. The good news is that demand for weight management services is high enough that relatively modest, well-targeted marketing can generate a significant volume of enquiries.

Your Website

A dedicated service page for your weight management clinic — clearly describing what you offer, who it is for, what the process involves, and what it costs — is the most important marketing asset you have. Patients searching for “weight management clinic [your town]” or “semaglutide pharmacy [your area]” need to land on a page that answers their questions clearly and makes it easy to book.

Your service page should include: a clear description of the service and medications offered, your eligibility criteria (this reduces ineligible enquiries), the consultation process, your pricing, and a prominent booking call-to-action. Patient testimonials, where you have consent to use them, significantly improve conversion rates.

Ensure your website is secure (HTTPS), loads quickly on mobile, and that your booking system is accessible directly from the service page without requiring the patient to navigate elsewhere.

Google Business Profile

Your Google Business Profile is one of the most powerful local marketing tools available, and it is free. Ensure your profile is complete and accurate, that your services include weight management, and that you are actively collecting patient reviews (via a post-appointment follow-up message). A pharmacy with forty recent reviews and an average rating above 4.5 stars will consistently outperform a competitor with fewer reviews in local search results.

Social Media

Educational content about weight management — the difference between GLP-1 medications, how BMI is calculated, what to expect in a weight management consultation — performs well on Facebook and Instagram, particularly with the demographic most likely to be interested in your service. Avoid making specific claims about weight loss outcomes, as this enters regulated territory.

The MHRA’s Blue Guide on advertising medicines is essential reading before you create any marketing materials that mention specific medications. You cannot advertise prescription-only medicines to the public, which means your marketing for a GLP-1 prescribing service must focus on the service and the clinic, not on the specific medications. Describing your service as a “weight management clinic with pharmacist prescribers who can assess you for all available treatment options” is appropriate. Naming semaglutide or tirzepatide and describing their weight loss results in promotional materials is not.

In-Pharmacy Marketing

Your existing pharmacy footfall is a ready audience for your weight management service. A simple A5 leaflet at the counter, a poster in the consultation room, and a brief mention by dispensary staff when dispensing medications associated with weight-related conditions (antihypertensives, statins, metformin) can generate significant referrals without any external marketing spend.

Train your pharmacy team to be aware of the service and comfortable directing patients towards it. A frontline member of staff saying “we do actually run a weight management clinic here if that’s something you’d be interested in — I can give you more information” is genuinely effective and costs nothing.

GP Liaison

Local GP practices are a potential source of patient referrals, and the relationship goes both ways. If you are providing a weight management service that includes thorough clinical governance, systematic GP notification, and appropriate escalation, you are providing something that helps GPs manage their own patient list. Sending a brief introductory letter to local practices — explaining your service, your prescriber qualifications, your governance framework, and how referrals work — can open referral pathways that generate a consistent stream of patients without any additional marketing expenditure.

You can learn more about the full range of clinical services supported by the RxSure platform and how to structure a multi-service private prescribing offering.

Frequently Asked Questions

Do I need to be an independent prescriber to run a weight management clinic in my pharmacy?

Yes, if you want to prescribe any weight management medications — including GLP-1 receptor agonists such as semaglutide and tirzepatide, or orlistat at the 120 mg prescription dose — you must hold the independent prescriber annotation on your GPhC registration. If you are a pharmacy owner without IP status, you can still operate a weight management clinic by employing or contracting a pharmacist independent prescriber to deliver clinical consultations. The clinical and governance responsibilities then sit with the prescribing pharmacist, not the pharmacy owner.

Can I prescribe semaglutide without a BMI requirement?

No. Wegovy (semaglutide 2.4 mg for weight management) is licensed for use in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Prescribing outside these criteria would be off-label, and while off-label prescribing is legally permissible where there is clinical justification, it comes with additional responsibility for the prescriber. The NICE NG246 guidance aligns with the licensed BMI thresholds, and departing from them without documented clinical rationale creates significant medicolegal exposure. Stick to the licensed indications unless you have specific specialist-level expertise in obesity medicine.

How do I handle a patient who is not losing weight on GLP-1 medication?

The first step is to review adherence — are they taking the medication as prescribed, at the correct dose? The next is to review their lifestyle factors, as GLP-1 medications work best alongside dietary changes and increased physical activity. If the patient is fully adherent and has reached the optimal maintenance dose without achieving at least 5% weight loss after 12 weeks, clinical guidance suggests that continuing pharmacotherapy is unlikely to be beneficial and treatment should be reviewed. This is a shared decision with the patient — some patients will prefer to trial a different medication, while others may wish to discontinue pharmacotherapy and focus on lifestyle approaches. Document your clinical reasoning clearly whatever the outcome.

What are my obligations if a patient reports a serious side effect?

If a patient reports a serious adverse event — severe abdominal pain, symptoms of pancreatitis, significant cardiovascular symptoms, or severe dehydration — your first responsibility is to the patient’s immediate safety. This may mean advising them to attend A&E, contacting their GP urgently, or calling 999 in an emergency. Once the immediate clinical situation is managed, you have a professional obligation to report the adverse event through the Yellow Card scheme (MHRA’s pharmacovigilance system) and to document the event in full in the patient’s clinical record. Serious adverse events should also be reviewed through your internal clinical governance process.

How should I handle the GLP-1 medication supply issues that have affected the market?

Supply constraints for GLP-1 medications, particularly semaglutide, have been a reality at various points since these medications became widely available. Your obligations when supply is limited are: to be transparent with patients about the supply situation as early as possible; to prioritise continuing treatment for patients who are already established on therapy over starting new patients; and to never recommend that patients source medications from unregulated online suppliers, as counterfeit GLP-1 medications have been identified in the UK market. If supply of one agent is unavailable, discuss whether switching to an available alternative is clinically appropriate for the individual patient.

How does the RxSure platform support weight management clinic operations specifically?

The RxSure platform provides the complete digital infrastructure for a pharmacy weight management service: online booking with integrated pre-screening questionnaires, structured clinical consultation templates, private prescription generation, automated GP notification letters, patient progress tracking with weight loss trend visualisation, integrated payment processing, and appointment reminder automation. The platform is built specifically for pharmacy private prescribing services in the UK, which means the clinical templates and governance tools are designed around the regulatory framework you are working within. You can review our pricing plans to find the option that works for your clinic volume.

Setting up a weight management clinic in your pharmacy is one of the most clinically meaningful and commercially rewarding decisions an independent prescribing pharmacist can make right now. The demand is there, the medications work, and the regulatory framework supports it. What distinguishes the clinics that build a strong, sustainable patient base from those that struggle is the quality of their clinical governance, the consistency of their patient pathway, and the professionalism of their digital infrastructure. Get those three things right, and you are building something that genuinely changes patients’ lives — while building a service your pharmacy can be proud of.